Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced a Research Forum to showcase its pipeline of next-generation ADCs. The event is scheduled for October 10, 2024, at 1:30 p.m. PT / 4:30 p.m. ET and will be accessible via live webcast.
Investors and interested parties can join the presentation by visiting https://ir.sutrobio.com/news-events/ir-calendar. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
This forum represents an opportunity for Sutro Biopharma to highlight its innovative approach to ADC development and provide insights into its near-term pipeline, potentially impacting investor interest and the company's stock performance.
Sutro Biopharma (NASDAQ: STRO), un'azienda oncologica in fase clinica specializzata in coniugati di farmaci anticorpali (ADC), ha annunciato un Forum di Ricerca per presentare il suo portafoglio di ADC di nuova generazione. L'evento è programmato per 10 ottobre 2024, alle 13:30 PT / 16:30 ET e sarà accessibile tramite webcast dal vivo.
Investitori e parti interessate possono partecipare alla presentazione visitando https://ir.sutrobio.com/news-events/ir-calendar. Per coloro che non possono assistere all'evento dal vivo, una registrazione dell'archivio sarà disponibile sul sito web dell'azienda dopo la presentazione.
Questo forum rappresenta un'opportunità per Sutro Biopharma di mettere in evidenza il suo approccio innovativo nello sviluppo di ADC e fornire approfondimenti sul suo portafoglio a breve termine, con potenziali ripercussioni sull'interesse degli investitori e sul rendimento delle azioni dell'azienda.
Sutro Biopharma (NASDAQ: STRO), una empresa oncológica en etapa clínica especializada en conjugados de medicamentos con anticuerpos (ADCs), ha anunciado un Foro de Investigación para mostrar su cartera de ADCs de nueva generación. El evento está programado para 10 de octubre de 2024, a las 1:30 p.m. PT / 4:30 p.m. ET y será accesible a través de una transmisión en vivo.
Los inversores y partes interesadas pueden unirse a la presentación visitando https://ir.sutrobio.com/news-events/ir-calendar. Para aquellos que no puedan asistir al evento en vivo, se pondrá a disposición una repetición archivada en el sitio web de la empresa después de la presentación.
Este foro representa una oportunidad para que Sutro Biopharma destaque su enfoque innovador en el desarrollo de ADC y proporcione información sobre su cartera a corto plazo, lo que podría impactar el interés de los inversores y el rendimiento de las acciones de la empresa.
수트로 바이오파마 (NASDAQ: STRO), 항체 약물 접합체 (ADC)에 전문화된 임상 단계의 종양학 회사가 차세대 ADC 파이프라인을 선보이기 위한 연구 포럼을 발표했습니다. 이 행사는 2024년 10월 10일 오후 1:30 PT / 오후 4:30 ET에 예정되어 있으며, 라이브 웹캐스트를 통해 접근할 수 있습니다.
투자자 및 관심 있는 관련자는 https://ir.sutrobio.com/news-events/ir-calendar를 방문하여 발표에 참여할 수 있습니다. 생중계 행사에 참석할 수 없는 분들을 위해 발표 후 회사 웹사이트에서 녹화된 재생본이 제공될 것입니다.
이번 포럼은 수트로 바이오파마가 ADC 개발에 대한 혁신적인 접근 방식을 강조하고 단기 파이프라인에 대한 인사이트를 제공할 수 있는 기회로, 투자자 관심 및 회사 주식 성과에 잠재적인 영향을 미칠 수 있습니다.
Sutro Biopharma (NASDAQ: STRO), une entreprise d'oncologie en phase clinique spécialisée dans les conjugués anticorps-médicament (ADC), a annoncé un Forum de Recherche pour mettre en avant son pipeline d'ADCs de nouvelle génération. L'événement est prévu pour le 10 octobre 2024 à 13h30 PT / 16h30 ET et sera accessible par webcast en direct.
Les investisseurs et les parties intéressées peuvent rejoindre la présentation en se rendant sur https://ir.sutrobio.com/news-events/ir-calendar. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion archivée sera disponible sur le site web de l'entreprise après la présentation.
Ce forum représente une opportunité pour Sutro Biopharma de mettre en avant son approche innovante du développement des ADC et de fournir des informations sur son pipeline à court terme, ce qui pourrait avoir un impact sur l'intérêt des investisseurs et sur la performance boursière de l'entreprise.
Sutro Biopharma (NASDAQ: STRO), ein auf klinische Stadien fokussiertes Onkologie-Unternehmen, das sich auf Antikörper-Wirkstoff-Konjugate (ADCs) spezialisiert hat, hat ein Forschungsforum angekündigt, um seine Pipeline der nächsten Generation von ADCs vorzustellen. Die Veranstaltung findet am 10. Oktober 2024, um 13:30 Uhr PT / 16:30 Uhr ET statt und ist über einen Live-Webcast zugänglich.
Investoren und interessierte Parteien können an der Präsentation teilnehmen, indem sie https://ir.sutrobio.com/news-events/ir-calendar besuchen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird nach der Präsentation eine archivierte Wiederholung auf der Website des Unternehmens verfügbar sein.
Dieses Forum stellt eine Gelegenheit für Sutro Biopharma dar, ihren innovativen Ansatz zur ADC-Entwicklung zu präsentieren und Einblicke in ihre kurzfristige Pipeline zu geben, was potenziell das Investoreninteresse und die Aktienperformance des Unternehmens beeinflussen kann.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.
Webcast Information:
To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
FAQ
When is Sutro Biopharma (STRO) hosting its Research Forum on next-generation ADCs?
How can investors access Sutro Biopharma's (STRO) Research Forum webcast?
What will Sutro Biopharma (STRO) discuss during its October 2024 Research Forum?
Will there be a replay available for Sutro Biopharma's (STRO) October 2024 Research Forum?
